Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P R Donald

Showing results (161-170 of 174) with videos related to

Pageof 18
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2004
The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazidP R Donald, F A Sirgel, A Venter, et al.
Immunogenetics|January 1, 1996
Identification of C to T mutation at position -236 bp in the human NRAMP1 gene promoterL A Lewis, T C Victor, E G Helden, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosisP R Donald, F A Sirgel, F J Botha, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 23, 2021
Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TBJ L Winckler, H S Schaaf, H R Draper, et al.
American Journal of Respiratory and Critical Care Medicine|May 1, 1997
Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosisD P Parkin, S Vandenplas, F J Botha, et al.
The Journal of Antimicrobial Chemotherapy|June 6, 2000
A multicentre study of the early bactericidal activity of anti-tuberculosis drugsF A Sirgel, P R Donald, J Odhiambo, et al.
Tuberculosis (Edinburgh, Scotland)|May 5, 2009
The clinical relevance of Mycobacterial pharmacogeneticsR M Warren, E M Streicher, N C Gey van Pittius, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 16, 2010
Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patientsA C Hesseling, G Walzl, D A Enarson, et al.
Antimicrobial Agents and Chemotherapy|March 7, 2012
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistanceA H Diacon, P R Donald, A Pym, et al.
Journal of Medical Microbiology|November 19, 1997
Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosisT C Victor, R Warren, J L Butt, et al.
Pageof 18

Showing results (161-170 of 174) with videos related to

Sort By:
Pageof 18
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2004
The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazidP R Donald, F A Sirgel, A Venter, et al.
Immunogenetics|January 1, 1996
Identification of C to T mutation at position -236 bp in the human NRAMP1 gene promoterL A Lewis, T C Victor, E G Helden, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosisP R Donald, F A Sirgel, F J Botha, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 23, 2021
Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TBJ L Winckler, H S Schaaf, H R Draper, et al.
American Journal of Respiratory and Critical Care Medicine|May 1, 1997
Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosisD P Parkin, S Vandenplas, F J Botha, et al.
The Journal of Antimicrobial Chemotherapy|June 6, 2000
A multicentre study of the early bactericidal activity of anti-tuberculosis drugsF A Sirgel, P R Donald, J Odhiambo, et al.
Tuberculosis (Edinburgh, Scotland)|May 5, 2009
The clinical relevance of Mycobacterial pharmacogeneticsR M Warren, E M Streicher, N C Gey van Pittius, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 16, 2010
Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patientsA C Hesseling, G Walzl, D A Enarson, et al.
Antimicrobial Agents and Chemotherapy|March 7, 2012
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistanceA H Diacon, P R Donald, A Pym, et al.
Journal of Medical Microbiology|November 19, 1997
Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosisT C Victor, R Warren, J L Butt, et al.
Pageof 18